By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Novogen Limited 

140 Wicks Road

North Ryde    NSW 2113  Australia
Phone: 203-327-1188 Fax: 203-327-0011



Company News
Novogen (NVGN) Release: GDC-0084 Progress Update: On Track For Phase II Commencement In 2017 8/22/2017 7:10:56 AM
Novogen (NVGN) Restructures, Board to Take Pay Cuts 8/14/2017 5:10:09 AM
Novogen (NVGN) Release: Progress Update On Cantrixil (TRXE-002-1) Development 8/7/2017 7:49:48 AM
Novogen (NVGN) Terminates Preclinical Program, Will Cut an Undisclosed Number of Jobs 4/6/2017 5:46:23 AM
C-Suite Shakeup: Novogen (NVGN) CEO North America, CSO and CFO Exit in Reorg 3/10/2017 5:45:41 AM
Novogen (NVGN) Awarded Grant Of Up To A$3m By Australian Federal Government For Novel Drug Discovery Program 3/6/2017 8:21:09 AM
Novogen Limited (NVGN) Acquires Privately-Held Neuro-Oncology Company To Support Development Of GDC-0084 In Glioblastoma 10/31/2016 6:48:10 AM
Genentech (RHHBY) Offloads Brain Drug to Tiny Australian Biotech Novogen (NVGN) for Bargain Price 10/31/2016 6:19:53 AM
Novogen Limited (NVGN) Release: Conversion Of Convertible Notes 9/14/2016 7:00:26 AM
Novogen Limited (NVGN) Release: US FDA Approves Investigational New Drug (IND) Application For Cantrixil(TM) (TRX-E-002-1) In Ovarian Cancer 9/12/2016 6:20:13 AM